Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year
Por um escritor misterioso
Descrição
Alteplase for Acute Ischemic Stroke - Pharmacy & Acute Care University
Thrombus composition and thrombolysis resistance in stroke - Research and Practice in Thrombosis and Haemostasis
Update on Management of Acute Ischemic Stroke in The Emergency Department
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis - The Lancet
Intravenous recombinant tissue plasminogen activator (IV rt-PA)
Impact of Tissue Plasminogen Activator on the Neurovascular Unit: From Clinical Data to Experimental Evidence - Denis Vivien, Maxime Gauberti, Axel Montagne, Gilles Defer, Emmanuel Touzé, 2011
Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18–64 years in the USA
Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review - Zhu - 2022 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
PDF) Prehospital thrombolysis in acute stroke: Results of the PHANTOM-S pilot study
Thrombolytic Therapy in Stroke: Ischemic Stroke and Neurologic Deficits, Clinical Trials, Thrombolysis Guidelines
Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial - The Lancet Neurology
Sonosensitive capsules for brain thrombolysis increase ischemic damage in a stroke model, Journal of Nanobiotechnology
